linjc16/ctgov huggingface dataset:
The Usefulness of Interferon-γ Release Assays and Tuberculin Skin Test for Detection of Latent Tuberculosis Infection

Study Overview
=================
Brief Summary
-----------------
The purposes of this study to compare the positivity of tuberculin skin test(TST) and QuantiFERON-TB Gold (QFT-G), and determine the level of agreement between two tests in patients with rheumatic diseases to evaluate the difference in the occurrence of active TB in patients who receive both QFT-G and TST compared with those who receive only TST for detecting of Latent tuberculosis infection(LTBI) who are candidates of TNF inhibitors.

Detailed Description
-----------------
Study Assessment The positive rates of QFT-G and TST as a screening test for LTBI The positive rates of QFT-G and TST will be analyzed Additional analysis will be performed according to the type of disease The agreement between QFT-G and TST as a screening test for LTBI The agreement between QFT-G and TST will be analyzed for patients with rheumatic diseases who examined both QFT-G and TST Additional analysis will be performed according to the type of disease The correlation of the occurrence of active TB and two tests (QFT-G and TST) The analysis of the correlation of the occurrence of active TB and two tests will be conducted for patients who have experienced anti-TNF agents 3-1. The occurrence of active TB in accordance with results of TST 3-2. The occurrence of active TB in accordance with results of QFT-G 3-3. The difference in the occurrence of active TB in patients performed both QFT-G and TST compared with those performed only TST for detecting of LTBI who are candidates of TNF inhibitors (pilot study).

Official Title
-----------------
Evaluation of the Usefulness of Interferon-γ Release Assays and Tuberculin Skin Test for Detection of Latent Mycobacterium Tuberculosis Infection in Korean Patients With Rheumatic Diseases

Conditions
-----------------
Rheumatic Disease, Rheumatoid Arthritis, Ankylosing Spondylitis, Tuberculosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with rheumatic diseases who examined TST or QFT-G in Hanyang university hospital from 2004 to 2010 Exclusion Criteria: N/A
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The agreement between QuantiFERON-TB Gold(QFT-G) and tuberculin skin test(TST) as a screening test for latent tuberculosis infection(LTBI) |  | one year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The correlation of the occurrence of active Tuberculosis and two tests (QuantiFERON-TB Gold (QFT-G) and tuberculosis skin test(TST)) |  | one year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
rheumatic disease, latent tuberculosis
The Use of Oral N-Acetyl Cysteine for the Treatment of Chronic Sinonasal Symptoms

Study Overview
=================
Brief Summary
-----------------
Chronic sinonasal symptoms (CSNS), such as coughing, throat clearing, nasal obstruction, crusting, dryness and discharge are extremely common in the general population. Although the physical symptoms are readily apparent, the psychosocial impact is often overlooked. Depression, anxiety, fear of social interaction, impaired personal relationships and decreased performance at work have all been associated with CSNS, often leading to multiple, frequent visits to the patient's primary care physician. A variety of clinical studies have shown that health-related quality of life (HRQoL) is significantly impaired in people with CSNS, with depressive symptoms being particularly common. CSNS may be due, in part, to tenacious nasal and paranasal secretions. It is therefore conceivable that a mucolytic may thin these secretions and improve mucociliary clearance, thereby reducing CSNS. N-acetylcysteine (NAC) is the most widely used mucolytic agent, particularly in patients with cystic fibrosis (CF), and has been documented as the most effective of the mucokinetic agents. Our group wishes to examine the use of NAC as a treatment for CSNS by testing the hypothesis that oral NAC reduces symptoms of CSNS compared to placebo.

Official Title
-----------------
The Use of Oral N-Acetyl Cysteine for the Treatment of Chronic Sinonasal Symptoms: A Randomized, Double-Blind, Placebo-Controlled Trial

Conditions
-----------------
Chronic Sinonasal Symptoms

Intervention / Treatment
-----------------
* Drug: N-Acetyl Cysteine
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: one or more the following symptoms: nasal stuffiness, nasal dryness or crusting, nasal congestion, discolored nasal discharge, or thick nasal discharge, for four or more days a week in the preceding two weeks Exclusion Criteria: poorly controlled asthma cystic fibrosis chronic obstructive pulmonary disease (COPD) severe coronary artery disease vasculopathy poorly controlled diabetes poorly controlled hypertension women who are breastfeeding

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: N-Acetyl Cysteine<br> | Drug: N-Acetyl Cysteine<br>* 600 mg PO BID<br>|
| Placebo Comparator: Placebo<br> | Drug: Placebo<br>* 1 tab PO BID<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sinonasal Outcomes Test (SNOT) - 22 |  | 6 weeks |
Fluid Challenges and Microcirculation

Study Overview
=================
Brief Summary
-----------------
The goal of this prospective observational study is to assess the impact of fluid challenge administration on macro and microcirculation in patients situated in the gray zone during a high risk abdominal surgery

Detailed Description
-----------------
Fluid optimization is a key goal in anesthesia. It allows to titrate fluid bolus based on flow variables or dynamic parameters of fluid responsiveness (pulse pressure variation (PPV) or stroke volume variation (SVV)). When PPV or SVV is above 13%, the patient will usually respond to a bolus of fluid while when PPV or SVV is below 9%, the patient will normally not respond to it. Between 9% and 13%, it is a gray zone where the effect of a fluid bolus is uncertain. The overall goal of fluid bolus administration is of course to optimize macrocirculation (stroke volume and cardiac output) but also (and probably more importantly) end organ tissue perfusion. However, regional tissue perfusion is not widely monitored during surgery. However, we do have some monitoring tools to assess microcirculation at the bedside. Investigation of microcirculation in addition to macro circulation may allow clinicians to know if a patient situated in the gray zone may or not increase microcirculation variables while macrocirculation variables are well known to be of little value to predict fluid responsiveness. The goal of this study is to assess microcirculation variables in patients situated in the gray zone (PPV between 9%-13%), and to assess macro and microcirculation responses to a standardized fluid challenge of 4 ml/kg of a balanced crystalloid solution.

Official Title
-----------------
Impact of Intraoperative Fluid Challenges Administration on Macro and Microcirculation in Patients Undergoing High-risk Abdominal Surgery and Situated in the Gray Zone of Pulse Pressure Variation

Conditions
-----------------
Surgery

Intervention / Treatment
-----------------
* Other: Fluid challenge


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients undergoing a high-risk abdominal surgery Patients equipped with a minimally invasive cardiac output monitoring device in order to optimize fluid administration Exclusion Criteria: Atrial fibrillation Ejection fraction <40%

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Fluid challenge|fluid challenge administration when patient is in the gray zone|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Microvascular flow index | Comparison of this index before and after the fluid challenge | day 0 |
/Autism Spectrum Disorder(ASD)Hearing Abnormalities Study

Study Overview
=================
Brief Summary
-----------------
Co morbidity rates of hearing loss in children with autism spectrum disorder are high and increasing. Investigators are aiming to: evaluate peripheral auditory and brain stem auditory function in children with autism spectrum disorder. compare communication capabilities in autistic children having hearing abnormalities and autistic children with normal hearing.

Detailed Description
-----------------
Full audiological evaluation is carried out to all participants including: pure tone and speech audiometry. Tympanometry and acoustic reflex threshold evaluation. Threshold auditory brain stem response for threshold determination in non co operative children not respond to pure tone,speech audiometry. Auditory brain stem response for neuro-otologic diagnosis. Transient evoked otoacoustic emissions in children proved to have normal hearing to detect minimal cochlear affection . Transient evoked otoacoustic emissions with contralateral masking. Communication evaluation is carried out to all participants using arabic language test(kotby et al,1995). Investigators use childhood autism rating scale for (CARS) for diagnosis of autism spectrum disorder.

Official Title
-----------------
Does Autism Spectrum Disorder(ASD)Show Any Degree of Hearing Abnormalities? :A Preliminary Study

Conditions
-----------------
Autism Spectrum Disorder

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Children aged 3-12 years diagnosed to have mild to moderate autism spectrum disorder diagnosed by childhood autism spectrum disorder(CARS 35% or less) Exclusion Criteria: children with otitis media with effusion. Associated neurological deficit .

Ages Eligible for Study
-----------------
Minimum Age: 3 Years
Maximum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| children with autism spectrum disorder<br>Children aged 3-12 years diagnosed to have mild to moderate autism spectrum disorder diagnosed by childhood autism spectrum disorder(CARS 35% or less) | |
| healthy non autistic age matched volunteers<br>children aged 3-12 years old never diagnosed to have autism spectrum disorder | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of autistic participants suffering from hearing abnormalities. | Invistigators choose autistic children attending phoniatric unit in assiut university from october 2017 to october 2020 as they will go under complete audiological evaluation. | 3 years from october 2017 to october 2020 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hearing and communication abnormalities
Hepcidin Levels in Periodontal Health and Disease

Study Overview
=================
Brief Summary
-----------------
Periodontal disease refers to inflammatory disease of the periodontium caused by the host and/or pathogenic microorganisms. Anti-inflammatory and pro-inflammatory cytokines play a role in the periodontal inflammation process. The aim of this study was to evaluate the levels of hepcidin, interleukin (IL)-6, and IL-10 levels in gingival crevicular fluid (GCF) and in serum samples obtained from individuals with periodontal inflammation.

Detailed Description
-----------------
The study included 90 individuals, who were divided into three groups: periodontally healthy (PH) (n=30); gingivitis (G) (n=30); and chronic periodontitis (CP) (n=30). GCF and serum samples were obtained from each individual, and samples were evaluated using ELISA. Statistical evaluation of the data was performed using the SPSS packet data program.

Official Title
-----------------
Gingival Crevicular Fluid and Serum Levels of Hepcidin, IL-6 and IL-10 in Periodontal Health and Disease

Conditions
-----------------
Periodontal Diseases

Intervention / Treatment
-----------------
* Other: Biomarker test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Systematically healthy patients. Patients who did not receive any medication or periodontal treatment within the previous 6 months Exclusion Criteria: Individuals who smoked and women who were pregnant and/or lactating were excluded from the study

Ages Eligible for Study
-----------------
Minimum Age: 32 Years
Maximum Age: 52 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group 1. Healthy individuals from periodontal perspective:<br>GI < 1, PD ≤ 3 mm, CAL = 0 mm, with no apparent bone loss on radiography. | Other: Biomarker test<br>* Diagnostic biomarker study<br>|
| Group 2. Individuals diagnosed with Gingivitis<br>GI > 1, PD ≤ 3 mm, CAL = 0 mm, with no apparent bone loss on radiography. | Other: Biomarker test<br>* Diagnostic biomarker study<br>|
| Group 3. Individuals diagnosed with CP<br>GI > 1, PD ≥ 5 mm, CAL ≥ 3 mm, with apparent bone loss on radiography. | Other: Biomarker test<br>* Diagnostic biomarker study<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hepcidin levels | Change in inflammatory phases | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| IL-6 levels | Change in inflammatory phases | 1 year | 
| IL-10 levels | Change in inflammatory phases | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
periodontal diseases, hepcidin, elisa, interleukin 6, interleukin 10
Biomagnetic Signals of Intestinal Ischemia II

Study Overview
=================
Brief Summary
-----------------
The lack of blood flow to the small intestine causes mesenteric ischemia. Using a Superconducting QUantum Interference Device (SQUID) which measures the magnetic field of the small intestine, we are hoping to identify abnormalities without surgical intervention.

Detailed Description
-----------------
The electrical activity of the small intestine may contain important information that will help us diagnose gastrointestinal diseases. The major impediment to reducing mortality of mesenteric ischemia is the lack of a noninvasive diagnostic test that identifies the syndrome before extensive necrosis occurs. Mesenteric ischemia is caused by the lack of blood flow to the intestine. The Superconducting QUantum Interference Device (SQUID) measures the magnetic field of the intestinal smooth muscle. By comparing normal smooth muscle and that of patients with mesenteric ischemia, the investigators hope to identify abnormal disease states without surgery.

Official Title
-----------------
Biomagnetic Signals of Intestinal Ischemia II

Conditions
-----------------
Ischemia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Normal subjects and those with diagnosed mesenteric ischemia Exclusion Criteria: Subjects who report a tendency toward claustrophobia

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Good blood flow<br>Group without any ischemia to the small intestine | |
| Poor blood flow<br>Group with partial ischemia to the small intestine | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To observe a difference in the magnetic activity between the normal and diseased smooth muscle of the small intestine |  | 2010 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Create mathematical and computer models of electrical activity of smooth muscle |  | 2010 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Blood supply, Mesentery
Comparison of Dynamic Contrast Enhanced CT and Diuretic Renogram in The Evaluation of UPJO

Study Overview
=================
Brief Summary
-----------------
Renal blood flow is inversely related to obstruction. We propose that this imaging will be as effective as the diuretic renogram in the functional diagnosis of obstruction. Furthermore, dynamic contrast CT scanning may also add anatomic information necessary for the surgical treatment.

Official Title
-----------------
Comparison of Dynamic Contrast Enhanced CT and Diuretic Renogram in The Evaluation of Ureteropelvic Junction Obstruction

Conditions
-----------------
Ureteral Obstruction

Intervention / Treatment
-----------------
* Procedure: Dynamic Contrast Enhanced CT & Diuretic Renogram


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years of age or older; Subjects suspected to have UPJO. Exclusion Criteria: Pregnancy; Renal failure (Creatinine >150); Allergy to contrast material; Ureteral stent; Nephrostomy tube; Renal pelvis calculi.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Dynamic Contrast Enhanced CT & Diuretic Renogram|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Collagen Analysis and Genetic Analysis of Families With Tendency to Hernias

Study Overview
=================
Brief Summary
-----------------
Analysis of collagen subtype subcutaneously and genetic analysis of patients from families with a tendency to hernias. Furthermore circulating biomarkers and biomarkers extracted from the subcutaneously tissue such as MMP's (matrix metallo proteinases) and TIMP's (tissue inhibitor of metallo proteinases) will be measured.

Detailed Description
-----------------
Research has shown relationship between hernias and collagen subtype I/III ratio, biomarkers such as MMP's TIMP's and other diseases such as Ehlers-Danlos, Marfans syndrome, AAA (abdominal aortic aneurysms), diverticulosis and rectal prolapse. Furthermore has research raised hypothesis about inheritance of hernias. The investigators are performing genetic examination combined with analysis of collagen and biomarkers on patients belonging to families with tendency to hernias. Other examinations performed on the patients enrolled in this study: Ultrasound (US) examination of the abdominal aorta to discover possible abdominal aortic aneurysms. Beightons score to evaluate the degree of joint hypermobility.

Official Title
-----------------
Collagen-subtype Analysis in Subcutaneous Tissue and Genetic Analysis on Patients From Families With a Tendency to Hernias

Conditions
-----------------
Hernia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: adults over 18 years adults must be members of a family where there are presence of hernias in minimum generation. Exclusion Criteria: infections pregnant mentally ill patients

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| control group<br> | |
| individuals from hernia-family<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Expression of collagen-genes or other relevant genes by microarray analysis compared with presence of hernia |  | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Amount of collagen subtypes measured subcutaneously. |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ventral, inguinal, hernia, inheritance, genetics
Anti-E1E2 (D32.10 Epitope-binding) Antibodies Status Prior Therapy Favors Direct-acting Antiviral Treatment Efficacy

Study Overview
=================
Brief Summary
-----------------
The hypothesis was to check whether baseline anti-E1E2 antibodies could predict virological outcome in Hepatitis C virus (HCV)-infected patients receiving direct-acting antiviral treatment

Detailed Description
-----------------
Presence of anti-E1E2 antibodies was previously associated with spontaneous cure of hepatitis C virus (HCV). The hypothesis was to check whether baseline anti-E1E2 antibodies could predict virological outcome in HCV-infected patients receiving direct-acting antiviral treatment

Official Title
-----------------
Anti-E1E2 (D32.10 Epitope-binding) Antibodies Status Prior Therapy Favors Direct-acting Antiviral Treatment Efficacy

Conditions
-----------------
Chronic Hepatitis c

Intervention / Treatment
-----------------
* Drug: Direct-acting antiviral therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years of age or older HCV patients treated with direct-acting antiviral treatment Patients with a prior treatment blood sample Patients with sustained virological response or virological relapse Exclusion Criteria: HIV or hepatitis B virus (HBV) coinfection

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Direct-acting antiviral therapy|HCV patients received direct-acting antiviral treatment for 12 or 24 weeks|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of patients with positive anti-E1E2 antibody level at treatment initiation | Anti-E1E2 antibody levels were determined using optical densities obtained after dilution of patients' serum samples at 1/250 and 1/500. Samples with anti-E1E2 levels above 950 (OD value× 1000) were considered positive | Baseline (treatment initiation day) |